Traws Pharma, Inc. — Director's Dealing 2018

May 2, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2018-04-27

Reporting Person: Hoffman Michael B (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-04-27	Common Stock	P	2211765	—	Acquired	3192438	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-27	Warrant (right to purchase)	$.425	P	2211765	Acquired		Series B Convertible Preferred Stock (55294.13)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8453	Indirect
Common Stock	1876	Direct

Footnotes

F1: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315).

F2: The warrants are exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and will expire on the 18-month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware.

F3: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust.